Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Core Insights - Alpha Tau Medical Ltd. reported a strong financial position with $76.9 million in cash and equivalents, supporting clinical advancements and commercial preparations [1][12] - The company has made significant progress in clinical trials and received marketing approval in Japan, marking a pivotal moment for its Alpha DaRT technology [2][4] Financial Performance - For the year ended December 31, 2025, R&D expenses increased to $32.1 million from $27.0 million in 2024, driven by higher employee compensation, raw material costs, and contractor expenses [8] - Marketing expenses decreased to $1.9 million from $2.3 million in 2024, while G&A expenses rose to $8.4 million from $6.7 million, primarily due to increased compensation and professional fees [9] - The company reported a net loss of $42.6 million, or $0.53 per share, compared to a net loss of $31.8 million, or $0.45 per share, in 2024 [11][23] Clinical and Regulatory Developments - Alpha Tau received marketing approval in Japan for Alpha DaRT in treating unresectable locally advanced or locally recurrent head and neck cancer, requiring a post-market surveillance study [6] - The company has five clinical trials approved in the U.S., including pivotal trials for skin cancer and pancreatic cancer, with significant milestones expected in the coming months [4][5] - Positive data from pancreatic cancer trials showed a 22% objective response rate and an 81% disease control rate across 32 patients [6] Manufacturing and Strategic Initiatives - Alpha Tau announced the receipt of a radioactive material license for its New Hampshire manufacturing facility, enabling commercial-scale production of Alpha DaRT [5] - The company is focused on expanding its manufacturing capabilities and engaging in strategic dialogues with potential partners to enhance the prospects for Alpha DaRT [2]